Tevogen Bio’s Founder and CEO, Ryan Saadi, Recognized as One of New Jersey’s Most Influential Business Leaders
Warren, N.J., February 28, 2025 – Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”), a clinical-stage specialty immunotherapy biotech company, is proud to announce that its Founder and CEO, Ryan Saadi, MD, MPH, has been named to the prestigious 2025 NJBIZ Power 100 list. This recognition honors the most influential figures shaping New Jersey’s business landscape, highlighting strategic leaders and innovators who drive progress and represent the state’s diversity.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotech company focused on developing novel immunotherapies for patients with cancer and infectious diseases. The company’s lead product candidate, TVGN-101, is a proprietary, off-the-shelf, allogeneic, anti-PD-L1 monoclonal antibody therapy, currently in phase 2 clinical trials for the treatment of various solid tumors. Tevogen Bio’s mission is to harness the power of the immune system to create transformative treatments for patients in need.
Ryan Saadi’s Leadership
Under Ryan Saadi’s leadership, Tevogen Bio has made significant strides in the biotech industry. Prior to founding Tevogen Bio, Dr. Saadi served as the Chief Medical Officer and Senior Vice President of Research and Development at Celldex Therapeutics, where he led the development of several immunotherapies, including Rintega (cediranib), which was approved by the FDA for the treatment of recurrent or persistent glioblastoma in 2014. Dr. Saadi’s expertise in immunotherapy and oncology has been instrumental in guiding Tevogen Bio’s research and development efforts.
Impact on the Local Community
This recognition is a testament to the vibrant biotech community in New Jersey. With a rich talent pool of scientists, researchers, and entrepreneurs, the state has become a hub for innovation in the life sciences sector. Tevogen Bio’s inclusion in the NJBIZ Power 100 list underscores the importance of this community and its role in driving progress in healthcare and medicine.
Global Implications
Beyond New Jersey, Tevogen Bio’s work in immunotherapy has the potential to impact patients worldwide. As the company continues to advance its lead product candidate, TVGN-101, through clinical trials, it brings hope to those battling various solid tumors. The recognition of Dr. Saadi as a leading business figure in New Jersey further validates the importance of continued investment in research and development in the biotech industry.
Conclusion
Tevogen Bio’s inclusion of its Founder and CEO, Ryan Saadi, in the 2025 NJBIZ Power 100 list is a significant achievement that highlights the company’s progress and the importance of the New Jersey biotech community. Under Dr. Saadi’s leadership, Tevogen Bio continues to make strides in the development of novel immunotherapies, with the potential to transform the lives of patients with cancer and infectious diseases. As the company advances its lead product candidate, TVGN-101, through clinical trials, the global implications of this work cannot be overstated.
- Tevogen Bio’s Founder and CEO, Ryan Saadi, named to the 2025 NJBIZ Power 100 list
- Recognition highlights strategic leaders and innovators shaping New Jersey’s business landscape
- Under Dr. Saadi’s leadership, Tevogen Bio continues to make strides in immunotherapy development
- New Jersey biotech community plays a vital role in healthcare and medicine innovation
- Tevogen Bio’s work in immunotherapy has the potential to impact patients worldwide
